Cortendo Appoints Robert Lutz As Chief Business Officer

Cortendo Appoints Robert Lutz As Chief Business Officer

GÖTEBORG, Sweden & RADNOR, Penn.--(BUSINESS WIRE)--Regulatory News: Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders, announced the appointment of Robert Lutz as Chief Business Officer.

Lutz brings deep experience in strategy, forecasting and commercialization from the specialty pharmaceutical industry, including more than a decade at Shire Pharmaceuticals. Lutz will lead the implementation of Cortendo's commercial strategy for COR-003 (levdexketoconazole), as well as business development and other corporate functions. 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.